KALA BIO is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe eye diseases. The company's pipeline centers on corneal and retinal conditions with limited treatment options. Its lead candidate, KPI-012, is in Phase 2b clinical trials for persistent corneal epithelial defects and limbal stem cell deficiency. The company also maintains KPI-014, a preclinical-stage program targeting rare inherited retinal diseases.
The company operates as a development-stage enterprise without significant commercial revenues, as its product candidates have not yet completed regulatory approval processes. KALA BIO was incorporated in Delaware in 2009 under the name Kala Pharmaceuticals, Inc. and rebranded to KALA BIO in August 2023. The company is headquartered in Arlington, Massachusetts and currently maintains a workforce of 38 full-time employees. The organization is listed on the Nasdaq exchange with a market capitalization of approximately $0.3 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-10.15 | $-10.15 | +41.5% | |
| 2023 | $-17.35 | $-17.35 | +41.1% | |
| 2022 | $-29.48 | $-29.48 | -1246.1% | |
| 2021 | $-2.19 | $-2.19 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-31 | 0001558370-25-004081 | SEC ↗ |
| 2023-12-31 | 2024-03-29 | 0001558370-24-004326 | SEC ↗ |
| 2022-12-31 | 2023-03-03 | 0001558370-23-002746 | SEC ↗ |
| 2021-12-31 | 2022-03-29 | 0001558370-22-004624 | SEC ↗ |
| 2020-12-31 | 2021-02-25 | 0001558370-21-001797 | SEC ↗ |
| 2019-12-31 | 2020-02-12 | 0001558370-20-000733 | SEC ↗ |
| 2018-12-31 | 2019-03-12 | 0001558370-19-001825 | SEC ↗ |
| 2017-12-31 | 2018-04-02 | 0001558370-18-002697 | SEC ↗ |